A Philadelphia judge has ruled that the scientific methodologies used by key plaintiffs’ expert witnesses in the 1,500 cases pending in the hormone replacement therapy mass tort litigation are not novel and are admissible in court.
Philadelphia Common Pleas Judge Sandra Mazer Moss ruled from the bench against a defense motion Wednesday. Moss said she was ruling from the bench because the experts are slated to testify in trials starting today and Monday in which plaintiffs allege their breast cancer was caused by drugs manufactured by Pfizer or other defendants.
